Sanofi and Invus led a $89m Series D round in Agomab.

Sanofi, a pharmaceutical company, and Invus, a private equity firm, led a $89m Series D round in Agomab, a biotechnology company developing therapies that aim to preserve and restore organ function in fibrotic diseases. “We are thrilled to have Sanofi and Invus joining our investor syndicate. Their investment as well as the continued support from our existing shareholders is another validation of the trailblazing work our team is conducting in the fields of fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. Through this financing round we will create further optionality and the capital will allow us to accelerate our efforts in developing our novel potential therapies,” Tim Knotnerus, Agomab Therapeutics CEO.